MUMBAI, India, Aug. 12 -- Intellectual Property India has published a patent application (202617079410 A) filed by Zhongshan Hospital, Fudan University on June 27, 2026, for Rabies Vaccine Immunogen Composition.
Inventors include Xu, Jianqing; Zhang, Xiaoyan; and Bai, Shimeng.
The application for the patent was published on August 07, 2026, under issue no. 32/2026.
Abstract: An anti-rabies virus immunogen composition capable of simultaneously inducing a humoral immune response and a cellular immune response and a use thereof. The anti-rabies virus immunogen composition involves a dual-immunogen combination, comprising a rabies virus glycoprotein G as an immunogen for activating neutralizing antibodies and a polymerase large protein L as a T-cell immunogen. The rabies virus glycoprotein is derived from the full length of a glycoprotein or extracellular region amino acids thereof or an antigenic fragment thereof, and the T-cell immunogen is derived from a recombinant sequence of a conserved region of a polymerase large protein. Optionally, the two immunogens are loaded onto the same type of carrier or different types of carriers. The vaccine is safe and can simultaneously activate anti-rabies virus T cells and an antibody response, thereby realizing combined protection for preventing and treating rabies virus infection.
Disclaimer: Curated by HT Syndication.
